Contact Us   |   Print Page   |   Sign In   |   Join
MichBio U: Using a Forecast to Drive Biopharma Decision Making for Products of All Stages
Tell a Friend About This EventTell a Friend

When: Wednesday, August 26, 2020
12:00 pm - 1:00 pm EST
Where: GoToWebinar
United States
Contact: Elizabeth Foster

Online registration is closed.
« Go to Upcoming Event List  


Have an idea for a webinar? Click here to fill out our webinar content form!


Register now for the next MichBio U webinar:


  Using a Forecast to Drive Biopharma Decision Making for Products of All Stages


Forecasts are a biopharma organization’s North Star. While initial product revenues may often be 5-10+ years in the future, the business exercise of developing a long-range forecast is critical to defining an asset’s value drivers and destroyers. While all forecast have limitations, the process forces companies to consider:

  • Are the true and diagnosed prevalences of our indication(s) evolving?
  • How safe and effective does our therapy need to be to warrant niche versus widespread utilization?
  • What patient-factors influence why a doctor would prescribe our drug?
  • How is the competitive environment going to evolve over the product’s lifecycle?
  • How many patients are likely to receive our drug?
  • What price is tractable given our TPP and the future reimbursement environment?
  • Will the indication’s insurance mix and/or site-of care erode our gross-to-net revenue?
  • What outcomes, biomarker, safety and health-economic data is needed to maximize the opportunity?

By answering the aforementioned questions and their logical adjacencies, companies can identify the actions that they to take today to realize their products full commercial potential while refining their companies value story for potential investors and partners.




Brad Plummer

Brad joined Trinity in 2017 as a member of the firm’s strategic advisory practice. Prior to joining Trinity, Brad trained as an academic scientist at Case Western Reserve University and then as a post-doc at the University of Michigan. At Case he focused on understanding arrhythmogenesis in the setting of genetic and acquired cardiomyopathies. While at Michigan, Brad developed polymer and protein-based non-viral CRISPR/Cas9 gene delivery platforms to treat cardiac disease. In his time at Trinity, Brad has worked with clients to develop foundational data-driven corporate strategies within cardiovascular disease and numerous orphan diseases. Specifically, his project work has included new product opportunity assessments, forecasting, portfolio planning, and patient flow.


Brad has published a book chapter and 9 journal articles in high-impact journals including: Circulation, PNAS & JBC. Brad holds a BS from Syracuse University and a PhD from Case Western Reserve University, all in Biomedical Engineering.



DATE: Wednesday, August 26, 2020

TIME: 12:00 PM to 1:00 PM EST


COST: Members – Complimentary; Non-Members - $19



*Webinar details will be emailed to attendees after registering. Questions? Contact Elizabeth Foster (310) 384-4807 or

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal